HIV / AIDS
HIV Drug Development News from IAS 2011 [VIDEO]
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 20 July 2011 00:00
Cal Cohen from the Community Research Institute of New England summarizes reports about experimental antiretroviral agents -- and new strategies for using existing drugs -- presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention this week in Rome. 
IAS 2011: Randomized Trial Supports Earlier Treatment
- Details
- Category: When to Start ART?
- Published on Wednesday, 20 July 2011 00:00
The large HPTN 052 trial, best known for showing that early antiretroviral treatment prevents HIV transmission, also found virological, immunological, and clinical benefit to starting HIV treatment sooner.
IAS 2011: Coronary Artery Calcification Linked to Bone Loss
- Details
- Category: HIV & Aging
- Published on Tuesday, 19 July 2011 00:00
Coronary artery calcification is associated with and low femoral bone mineral density (BMD), but no such link found with lumbar spine BMD, researchers reported at IAS 2011 in Rome.
IAS 2011: Once-daily Elvitegravir Matches Twice-daily Raltegravir
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 20 July 2011 00:00
The experimental HIV integrase inhibitor elvitegravir works as well as raltegravir (Isentress) for treatment-experienced people with extensive drug resistance, and was well-tolerated overall, according to data presented at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) this week in Rome. 
IAS 2011: Stakeholders Call for HIV Cure Research
- Details
- Category: Search for a Cure
- Published on Tuesday, 19 July 2011 00:00
Over the past few years a cure for HIV has again become a goal of HIV/AIDS research. The International AIDS Society is a leading proponent of greater investment in cure-related science. 
IAS 2011: The Proof is Here: HIV Treatment is HIV Prevention
- Details
- Category: Treatment as Prevention/Test & Treat
- Published on Tuesday, 19 July 2011 00:00
Antiretroviral treatment was shown to prevent HIV infection in the large, randomized trial HPTN 052 trial, reducing risk by 96%, researchers reported at IAS 2011 this week in Rome.
"There is a clinical benefit for the patient and a dramatic, nearly 100% reduction in transmission," said lead investigator Myron Cohen. "We can't get much better." 
IAS 2011: HIV Treatment as Prevention: HPTN 052 Offers Proof [VIDEO]
- Details
- Category: Treatment as Prevention/Test & Treat
- Published on Tuesday, 19 July 2011 00:00
HPTN 052 lead investigator Myron Cohen talked to Paul Dalton from HIVandHepatitis.com about the study's findings and their significance. 
Web Design and Development by